The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments. Key emerging therapies like Amivantamab, BNT113, and Petosemtamab are expected to transform treatment options and expand the market, which was valued at USD 850 million in 2025 across major markets including the US, EU4, UK, and Japan. Advances in immunotherapy, precision medicine, and combination treatments are improving outcomes for patients, while ongoing clinical trials and regulatory designations signal a dynamic and competitive landscape ahead.
